Pharmacokinetic Evaluation of Newly Developed Oral Immediate Releaseand Sustained Release Dosage Forms of Losartan Potassium

The aim of our present study is to develop oral sustained release dosage form for Losartan Potassium (SS) with wet granulation technique. Xanthan gum with additives MCC PH101 was used for the present study. The dissolution study is carried out. The studies indicated that the drug release can be modulated by varying the concentration of the polymer and fillers. The pharmacokinetic parameters including AUC 0–t , AUC 0–∞ , C max , T max , T 1/2 , and elimination rate constant ( K el ) were determined from plasma concentration of both formulations of Immediate Release (Losartan Potassium 1.75 mg tablets) and Sustained Release (Losartan Potassium 3.5 mg tablets). The absorption of drug from the sustained release tablets was significantly higher than that for the reference Losartan Potassium tablet because of longer half-life and lower elimination. Different pharmacokinetic parameters including AUC 0-t , AUC 0-∞ , C max , T max , T 1/2 , and K eli were determined from plasma concentration of both Sustained and Immediate release tablets.

[1]  G. R. Pereira,et al.  Multivariate optimization and validation of an analytical methodology by RP-HPLC for the determination of losartan potassium in capsules. , 2009, Talanta.

[2]  L. Sasongko,et al.  Simultaneous quantification of losartan and active metabolite in human plasma by liquid chromatography-tandem mass spectrometry using irbesartan as internal standard. , 2009, Journal of pharmaceutical and biomedical analysis.

[3]  R. J. Tyrrell,et al.  Development and validation of a stability-indicating HPLC method for the simultaneous determination of losartan potassium, hydrochlorothiazide, and their degradation products. , 2002, Journal of pharmaceutical and biomedical analysis.

[4]  N. Erk Analysis of binary mixtures of losartan potassium and hydrochlorothiazide by using high performance liquid chromatography, ratio derivative spectrophotometric and compensation technique. , 2001, Journal of pharmaceutical and biomedical analysis.

[5]  Teven,et al.  EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .

[6]  Z. Zhao,et al.  Identification of losartan degradates in stressed tablets by LC-MS and LC-MS/MS. , 1999, Journal of pharmaceutical and biomedical analysis.

[7]  D. Sica,et al.  Simple high-performance liquid chromatographic method for determination of losartan and E-3174 metabolite in human plasma, urine and dialysate. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[8]  M. Lo,et al.  An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection. , 1997, Journal of pharmaceutical and biomedical analysis.